Background
Phase 3, multicenter, randomized, open-label trial (COG AALL1731, NCT03914625). N>4,000 enrolled, 1,440 randomized (718 blinatumomab, 722 control), children and young adults aged 1–21 with newly diagnosed NCI standard-risk (SR) B-cell ALL. SR-Average (SR-Avg) and SR-High patients (not SR-Low) were randomized based on cytogenetics, MRD, and biologic features. Two non-sequential 28-day blinatumomab cycles were added to the standard COG backbone. Trial stopped early at first interim analysis for overwhelming efficacy. Published NEJM 2024.
Interventions and follow up
Arm A (control): Standard COG backbone chemotherapy (induction, consolidation, interim maintenance, delayed intensification, maintenance) without blinatumomab (N=722)
Arm B (blinatumomab): Standard COG backbone + two 28-day blinatumomab cycles (15 µg/m²/day) incorporated non-sequentially (N=718)
Primary endpoint: 3-year disease-free survival (DFS)
mFollow up: Interim analysis (trial stopped early for efficacy)
Arm B (blinatumomab): Standard COG backbone + two 28-day blinatumomab cycles (15 µg/m²/day) incorporated non-sequentially (N=718)
Primary endpoint: 3-year disease-free survival (DFS)
mFollow up: Interim analysis (trial stopped early for efficacy)
Results
3-year DFS (primary): 96.0±1.2% (blinatumomab + chemo) vs 87.9±2.1% (chemo alone), HR 0.39 (95% CI 0.24–0.64), P<.0001 — exceeded interim efficacy boundary
3-year OS: Not mature at interim
Subgroups: Benefit consistent across SR-Avg and SR-High; blinatumomab mitigated adverse impact of day-29 MRD and high-risk cytogenetics
3-year OS: Not mature at interim
Subgroups: Benefit consistent across SR-Avg and SR-High; blinatumomab mitigated adverse impact of day-29 MRD and high-risk cytogenetics
Adverse events
Blinatumomab-specific: Grade ≥3 neurologic events at a low rate consistent with the established profile; CRS rare in standard-risk ALL; no new safety signals
Backbone toxicity: Overall AE rates comparable between arms (asparaginase allergy, neutropenic fever, mucositis)
Backbone toxicity: Overall AE rates comparable between arms (asparaginase allergy, neutropenic fever, mucositis)
Conclusions
Adding two 28-day blinatumomab cycles to standard chemotherapy improved 3-year DFS from 87.9% to 96.0% (HR 0.39, P<.0001) in children and young adults with NCI standard-risk B-ALL. This is the largest DFS improvement seen in a standard-risk pediatric ALL trial and constitutes a paradigm shift in a highly curable disease.
Key Limitations
Interim analysis — OS immature and longer follow-up needed for late effects and durability. Blinatumomab adds cost, complexity, and infusion infrastructure (continuous IV over 28 days), challenging resource-limited settings. The SR-Low group was not randomized. Absolute DFS gain of 8.1% in an already ~88%-curable group implies ~12 patients treated to prevent one relapse, raising cost-benefit considerations. Long-term pediatric neurocognitive outcomes from blinatumomab are not yet known.
Clinical Context
AALL1731 is immediately practice-changing: blinatumomab + standard chemotherapy is emerging as the standard of care for NCI standard-risk B-ALL in pediatric and young adult patients, and an expanded FDA frontline indication is anticipated. COG protocols are being updated; ESMO/ASCO discussion is ongoing. International adoption depends on infrastructure for continuous IV infusion. Together with ECOG E1910 (adults) and GIMEMA LAL2317, it solidifies blinatumomab's role across the B-ALL spectrum.